The study met its primary objective of demonstrating statistically greater improvement from baseline in Eczema Area and Severity Index score at 16 weeks versus placeboPatients receiving KHK4083/AMG 451 showed statistically greater improvements in additional secondary efficacy endpoints versus placeboKHK4083/AMG 451.